21 January 2026
21 January 2026
Pfizer exits ViiV Healthcare with a $1.89bn payout, while GSK retains its majority stake amid the shareholder shake-up.
Pfizer will now employ Novavax’s adjuvant, Matrix-M, into its vaccines across two disease areas.
The partnership aims to deploy AI capabilities that automatically analyse X-ray and CT images to assist radiologists.
Aspect will acquire rights from Novo Nordisk to stem cell-derived islet cell and hypoimmune cell engineering technologies.
In December 2025, the UK Government announced a landmark pharmaceuticals agreement with the US that secures tariff-free access to the world’s largest medicines market and reshapes domestic pricing rules to accelerate patient access to innovative treatments.
Dr Karsten Eastman, CEO, Sethera Therapeutics, highlights the challenges around ‘true’ diversification in DNA libraries.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
